• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病患者神经精神症状的诊断与管理。

Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease.

机构信息

Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.

出版信息

Curr Psychiatry Rep. 2018 Oct 27;20(12):117. doi: 10.1007/s11920-018-0978-8.

DOI:10.1007/s11920-018-0978-8
PMID:30367272
Abstract

PURPOSE OF REVIEW

To explore the most recent developments in the effective diagnosis and treatment of neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD).

RECENT FINDINGS

The clinical diagnosis of NPS in AD is facilitated by the use of the Neuropsychiatric Inventory (NPI). CT and MRI scans can be useful for detecting structural changes indicating AD. Other promising diagnostic methodologies that are less frequently used in the clinical setting include positron emission tomography (PET) scans for detecting amyloid and blood tests for detecting serum biomarkers. Numerous pharmaceutical agents have been studied for their use in managing NPS, with antipsychotics being popular for managing agitation but also having significant side effects. Non-pharmacological interventions, such as reminiscence therapy and the Describe, Investigate, Create, Evaluate (DICE) approach may be able to provide treatment without such adverse effects. Diagnosing AD and the comorbid NPS remains primarily a clinical endeavor with CT and MRI scans sometimes used, but evidence is amassing for the use of other imaging modalities and different lab tests for convenient and empiric diagnosis of AD to distinguish it from other psychiatric illnesses. The number of pharmacologic treatments for NPS that are safe as well as efficacious remains limited, yet non-pharmacologic interventions have clear clinical utility. In addition to searching for more successful pharmacological treatments, further research should focus on novel diagnostic tests and non-pharmacologic therapies.

摘要

目的综述

探讨阿尔茨海默病(AD)患者神经精神症状(NPS)有效诊断和治疗的最新进展。

最新发现

使用神经精神问卷(NPI)有助于 AD 患者 NPS 的临床诊断。CT 和 MRI 扫描可用于检测表明 AD 的结构变化。其他有前途的诊断方法在临床环境中使用较少,包括正电子发射断层扫描(PET)用于检测淀粉样蛋白和血液测试用于检测血清生物标志物。已经研究了许多药物来治疗 NPS,抗精神病药常用于治疗激越,但也有显著的副作用。非药物干预,如怀旧疗法和描述、调查、创造、评估(DICE)方法,可能能够提供没有这种副作用的治疗。AD 和合并的 NPS 的诊断主要仍是临床工作,有时会使用 CT 和 MRI 扫描,但越来越多的证据表明,使用其他成像方式和不同的实验室测试可以方便地进行 AD 的经验诊断,将其与其他精神疾病区分开来。安全有效的 NPS 治疗药物数量仍然有限,但非药物干预具有明显的临床实用性。除了寻找更成功的药物治疗方法外,还应进一步研究新的诊断测试和非药物治疗方法。

相似文献

1
Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease.阿尔茨海默病患者神经精神症状的诊断与管理。
Curr Psychiatry Rep. 2018 Oct 27;20(12):117. doi: 10.1007/s11920-018-0978-8.
2
Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.治疗激越的进展:阿尔茨海默病中的一项重大临床挑战。
Expert Opin Pharmacother. 2015;16(17):2581-8. doi: 10.1517/14656566.2015.1092520. Epub 2015 Sep 21.
3
Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.痴呆症老年人行为和心理症状的慢性抗精神病药物撤药与继续用药对比
Cochrane Database Syst Rev. 2013 Mar 28(3):CD007726. doi: 10.1002/14651858.CD007726.pub2.
4
A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).一项双盲随机安慰剂对照撤药试验,比较美金刚与抗精神病药物对阿尔茨海默病患者功能和神经精神症状的长期治疗效果(MAIN-AD)。
J Am Med Dir Assoc. 2015 Apr;16(4):316-22. doi: 10.1016/j.jamda.2014.11.002. Epub 2014 Dec 15.
5
6
Antipsychotics in Alzheimer's Disease: Current Status and Therapeutic Alternatives.抗精神病药物在阿尔茨海默病中的应用:现状与治疗选择
Curr Alzheimer Res. 2023;20(10):682-691. doi: 10.2174/0115672050287534240215052417.
7
Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study.阿尔茨海默病中神经精神改善与神经认知变化的相关性:CATIE-AD 研究分析。
J Alzheimers Dis. 2018;66(1):139-148. doi: 10.3233/JAD-180304.
8
A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.2023年阿尔茨海默病激越治疗进展更新
Expert Opin Pharmacother. 2023 Apr;24(6):691-703. doi: 10.1080/14656566.2023.2195539. Epub 2023 Mar 28.
9
An update on the advancements in the treatment of agitation in Alzheimer's disease.阿尔茨海默病激越治疗进展的最新情况。
Expert Opin Pharmacother. 2017 Apr;18(6):611-620. doi: 10.1080/14656566.2017.1307340. Epub 2017 Mar 28.
10
Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.与司美格鲁肽治疗阿尔茨海默病相关的神经精神科问卷变化
J Alzheimers Dis. 2016 Aug 10;54(1):373-81. doi: 10.3233/JAD-151113.

引用本文的文献

1
Obesity and Alzheimer's disease dementia: Examining inflammatory links to cognitive decline and neuropsychiatric symptoms.肥胖与阿尔茨海默病性痴呆:探讨炎症与认知衰退及神经精神症状的关联。
J Alzheimers Dis. 2025 Jul;106(1):51-53. doi: 10.1177/13872877251338467. Epub 2025 May 6.
2
Creativity and Mental Illness: A Case Study of a Patient with Progressive Bulbar Palsy.创造力与精神疾病:一例进行性延髓麻痹患者的病例研究
Brain Sci. 2024 Nov 22;14(12):1171. doi: 10.3390/brainsci14121171.
3
Lattice 123 pattern for automated Alzheimer's detection using EEG signal.

本文引用的文献

1
The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.胆碱能系统在阿尔茨海默病的病理生理学和治疗中的作用。
Brain. 2018 Jul 1;141(7):1917-1933. doi: 10.1093/brain/awy132.
2
Analysis of microRNA and Gene Expression Profiles in Alzheimer's Disease: A Meta-Analysis Approach.阿尔茨海默病中 microRNA 和基因表达谱的分析:荟萃分析方法。
Sci Rep. 2018 Mar 19;8(1):4767. doi: 10.1038/s41598-018-20959-0.
3
High performance plasma amyloid-β biomarkers for Alzheimer's disease.用于阿尔茨海默病的高性能血浆淀粉样蛋白-β生物标志物。
用于使用脑电图信号自动检测阿尔茨海默病的点阵123模式。
Cogn Neurodyn. 2024 Oct;18(5):2503-2519. doi: 10.1007/s11571-024-10104-1. Epub 2024 Apr 3.
4
Future Therapeutic Strategies for Alzheimer's Disease: Focus on Behavioral and Psychological Symptoms.阿尔茨海默病的未来治疗策略:关注行为和心理症状。
Int J Mol Sci. 2024 Oct 22;25(21):11338. doi: 10.3390/ijms252111338.
5
Cognition Mediates the Association Between Cerebrospinal Fluid Biomarkers of Amyloid and P-Tau and Neuropsychiatric Symptoms.认知功能在脑脊液淀粉样蛋白和磷酸化 tau 生物标志物与神经精神症状之间的关联中起中介作用。
J Alzheimers Dis. 2024;100(3):1055-1073. doi: 10.3233/JAD-240125.
6
Microglia-targeted inhibition of miR-17 via mannose-coated lipid nanoparticles improves pathology and behavior in a mouse model of Alzheimer's disease.通过甘露糖包裹的脂质纳米颗粒靶向抑制小胶质细胞中的 miR-17 改善阿尔茨海默病小鼠模型的病理和行为。
Brain Behav Immun. 2024 Jul;119:919-944. doi: 10.1016/j.bbi.2024.05.006. Epub 2024 May 7.
7
Preoperative symptoms of depression, anxiety, and cognitive impairment in glioma patients: A cerebral perfusion CT study.脑胶质瘤患者术前抑郁、焦虑和认知障碍的症状:一项脑灌注 CT 研究。
Brain Behav. 2023 Jun;13(6):e3020. doi: 10.1002/brb3.3020. Epub 2023 May 1.
8
Characterization of apathy-like behaviors in the 5xFAD mouse model of Alzheimer's disease.阿尔茨海默病 5xFAD 小鼠模型中类淡漠行为的特征。
Neurobiol Aging. 2023 Jun;126:113-122. doi: 10.1016/j.neurobiolaging.2023.02.012. Epub 2023 Mar 2.
9
Relationship between , , and Genetic Variants and Neuropsychiatric Symptoms in Patients with Alzheimer's Disease.阿尔茨海默病患者 、 、 和 基因变异与神经精神症状的关系。
Int J Environ Res Public Health. 2023 Mar 1;20(5):4412. doi: 10.3390/ijerph20054412.
10
Impaired Dopamine Release and Latent Learning in Alzheimer's Disease Model Zebrafish.阿尔茨海默病模型斑马鱼多巴胺释放受损和潜在学习能力下降。
ACS Chem Neurosci. 2022 Oct 5;13(19):2924-2931. doi: 10.1021/acschemneuro.2c00484. Epub 2022 Sep 16.
Nature. 2018 Feb 8;554(7691):249-254. doi: 10.1038/nature25456. Epub 2018 Jan 31.
4
The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.《痴呆症哌醋甲酯试验 2 中的淡漠(ADMET 2):一项随机对照试验研究方案》。
Trials. 2018 Jan 18;19(1):46. doi: 10.1186/s13063-017-2406-5.
5
Up-regulated Pro-inflammatory MicroRNAs (miRNAs) in Alzheimer's disease (AD) and Age-Related Macular Degeneration (AMD).阿尔茨海默病(AD)和年龄相关性黄斑变性(AMD)中上调的促炎 microRNAs(miRNAs)。
Cell Mol Neurobiol. 2018 Jul;38(5):1021-1031. doi: 10.1007/s10571-017-0572-3. Epub 2018 Jan 4.
6
Peripheral inflammation in prodromal Alzheimer's and Lewy body dementias.前驱期阿尔茨海默病和路易体痴呆的周围炎症。
J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):339-345. doi: 10.1136/jnnp-2017-317134. Epub 2017 Dec 16.
7
Electroconvulsive Therapy for Agitation and Aggression in Dementia: A Systematic Review.电抽搐治疗痴呆激越和攻击行为的系统评价。
Am J Geriatr Psychiatry. 2018 Apr;26(4):419-434. doi: 10.1016/j.jagp.2017.09.023. Epub 2017 Sep 25.
8
Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.用于治疗痴呆患者激越或精神病性症状的抗精神病药物。
JAMA. 2017 Sep 19;318(11):1057-1058. doi: 10.1001/jama.2017.11112.
9
Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.美金刚治疗轻度阿尔茨海默病社区居住老年退伍军人淡漠症状的双盲、随机、安慰剂对照试验
Am J Psychiatry. 2018 Feb 1;175(2):159-168. doi: 10.1176/appi.ajp.2017.17030316. Epub 2017 Sep 15.
10
Distinguishing Depressive Pseudodementia from Alzheimer Disease: A Comparative Study of Hippocampal Volumetry and Cognitive Tests.区分抑郁性假性痴呆与阿尔茨海默病:海马体积测量与认知测试的比较研究
Dement Geriatr Cogn Dis Extra. 2017 Jul 4;7(2):230-239. doi: 10.1159/000477759. eCollection 2017 May-Aug.